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This issue of BJD includes an interesting article considering the cost-effectiveness of HLA-B*15:02 
screening in Malaysia [1]. Adverse drug reactions (ADRs) are a major cause of iatrogenic morbidity, 
mortality and treatment costs [2,3,4]. Strategies to avoid ADRs, including pharmacogenetic 
prediction, have clear therapeutic potential. There is strong evidence associating HLA-B*15:02 with 
increased susceptibility to severe cutaneous ADRs, including Stevens-Johnson syndrome (SJS) and 
toxic-epidermal necrolysis (TEN), in patients prescribed carbamazepine. Consequently, the US Food 
and Drug Administration requires (and the Health Canada Santé Canada recommends) screening 
prior to initiation of carbamazepine for patients with ancestry from genetically at-risk populations 
[5]. 
Economic evaluations of HLA-B*15:02 screening indicate that routine testing may be cost-effective 
in Thai and Singaporean populations, however results are sensitive to allele prevalence and choice of 
comparator [6,7,8]. In this issue, Chong and colleagues present a decision-analytic model to assess 
the cost-effectiveness of screening for HLA-B*15:02 in an ethnically diverse population of Malaysian 
epilepsy patients. The analysis compares realistic strategies of universal carbamazepine initiation 
without screening (current practice); universal screening for HLA-B*15:02 with carbamazepine or 
sodium valproate prescribed depending on test result; and universal prescription of sodium 
valproate. In cases of treatment failure with sodium valproate, topiramate is assumed as a third line 
option. The analysis is conducted from a Malaysian societal perspective, and is therefore inclusive of 
patient and carer out-of-pocket expenses and productivity loss. Results are reported over a lifetime 
horizon capturing the full effects of SJS/TEN sequelae and the impact of alternative treatments. 
The results of the base-case analysis indicate that current practice is both less costly and more 
effective than either alternative strategy, hence, screening is unlikely to be cost-effective in 
Malaysia.  
This contrasts with previous studies, principally by accounting for the long-term differential impacts 
of the evaluated antiepileptic drugs on seizure control. This is consistent with other economic 
evaluations of pharmacogenetics in epilepsy [9] and follows good modelling practice in taking full 
consideration of downstream costs and effects [10]. Consequently, as sodium valproate is less 
effective than carbamazepine in achieving seizure remission, unnecessary changes in prescription 
(e.g. because of false positive test results) will lead to less effective control of epilepsy, and offset 
the benefits of testing. 
The economic model predicts that screening 222 patients will avoid 1 case of SJS/TEN, but at the 
expense of 3 additional patients having uncontrolled epilepsy. The utility experienced in these 3 
patients (0.69) compared to those in remission (0.96) goes some way to counter the gains made 
through the avoidance of one SJS/TEN event associated with a utility of 0.29. 
The authors use a (published) local study to inform the parameter value for mortality (4.2%); 
significantly lower than is typically quoted for SJS/TEN (15%-50%) [3,4]. It would perhaps have been 
interesting to see the impact of this parameter on cost-effectiveness, but also highlights that with 
improved recognition and diagnosis, that survival outcomes can be improved, which should be 
acknowledged in future economic evaluations. 
The findings of this evaluation highlight the importance of carrying out robust, population-specific 
economic analyses to best inform local evidence-based policy. 
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